Encompass Health (NYSE:EHC – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.
Insider and Institutional Ownership
97.3% of Encompass Health shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 1.8% of Encompass Health shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Encompass Health and Mangoceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Encompass Health | 10.01% | 18.08% | 8.22% |
| Mangoceuticals | -4,794.60% | -96.39% | -89.60% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Encompass Health | 0 | 1 | 6 | 1 | 3.00 |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
Encompass Health presently has a consensus price target of $146.83, indicating a potential upside of 21.40%. Given Encompass Health’s stronger consensus rating and higher possible upside, analysts plainly believe Encompass Health is more favorable than Mangoceuticals.
Risk & Volatility
Encompass Health has a beta of 0.75, suggesting that its stock price is 25% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.
Earnings & Valuation
This table compares Encompass Health and Mangoceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Encompass Health | $5.94 billion | 2.01 | $566.20 million | $6.14 | 19.70 |
| Mangoceuticals | $460,000.00 | 18.05 | -$20.64 million | ($1.01) | -0.38 |
Encompass Health has higher revenue and earnings than Mangoceuticals. Mangoceuticals is trading at a lower price-to-earnings ratio than Encompass Health, indicating that it is currently the more affordable of the two stocks.
Summary
Encompass Health beats Mangoceuticals on 12 of the 15 factors compared between the two stocks.
About Encompass Health
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions. It offers services through the Medicare program to federal government, managed care plans and private insurers, state governments, and other patients. The company was formerly known as HealthSouth Corporation and changed its name to Encompass Health Corporation in January 2018. The company was incorporated in 1984 and is based in Birmingham, Alabama.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.
